PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic, Inc. (TBIO)
6/11/2012 9:56:25 AM
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB:TBIO) announced that the US Patent and Trademark Office has issued patent number US 8,137,919 entitled “Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including Cetuximab, Panitumumab and Erlotinib”. The patent was exclusively licensed to Transgenomic by the Montefiore Medical Center (Bronx, NY, US) and includes all tumor types and targeted therapies that may be influenced by PIK3CA mutation status.
comments powered by